Chemical Compound Review:
Impavido 2-(hexadecoxy-oxido- phosphoryl)oxyethyl...
Synonyms:
Miltefos, Miltex, Miltefosina, Miltefosine, HDPC, ...
This record was replaced with 3600.
- Miltefosine for visceral leishmaniasis. Eibl, H. N. Engl. J. Med. (2000)
- Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. Jha, T.K., Sundar, S., Thakur, C.P., Bachmann, P., Karbwang, J., Fischer, C., Voss, A., Berman, J. N. Engl. J. Med. (1999)
- Miltefosine in recurrent cutaneous breast cancer. Clive, S., Leonard, R.C. Lancet (1997)
- Transcriptional activation of p21(waf1/cip1) by alkylphospholipids: role of the mitogen-activated protein kinase pathway in the transactivation of the human p21(waf1/cip1) promoter by Sp1. De Siervi, A., Marinissen, M., Diggs, J., Wang, X.F., Pages, G., Senderowicz, A. Cancer Res. (2004)
- Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine. Hanson, P.K., Malone, L., Birchmore, J.L., Nichols, J.W. J. Biol. Chem. (2003)
- Drug resistance in leishmaniasis. Croft, S.L., Sundar, S., Fairlamb, A.H. Clin. Microbiol. Rev. (2006)
- A pathway for phosphatidylcholine biosynthesis in Plasmodium falciparum involving phosphoethanolamine methylation. Pessi, G., Kociubinski, G., Mamoun, C.B. Proc. Natl. Acad. Sci. U.S.A. (2004)
- Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Ruiter, G.A., Zerp, S.F., Bartelink, H., van Blitterswijk, W.J., Verheij, M. Cancer Res. (1999)
- Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Uberall, F., Oberhuber, H., Maly, K., Zaknun, J., Demuth, L., Grunicke, H.H. Cancer Res. (1991)
- Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. Pérez-Victoria, F.J., Sánchez-Cañete, M.P., Castanys, S., Gamarro, F. J. Biol. Chem. (2006)
- Opposite effect of miltefosine on the antineoplastic activity and haematological toxicity of cyclophosphamide. Stekar, J., Hilgard, P., Klenner, T. Eur. J. Cancer (1995)
- Effect of ether lipids on mouse granulocyte-macrophage progenitor cells. Vehmeyer, K., Kim, D.J., Nagel, G.A., Eibl, H., Unger, C. Cancer Chemother. Pharmacol. (1989)
- Cellular uptake and retention measurements of alkylphosphocholines in the SK-BR-3 breast cancer and Molt-4 leukemia cell line using capillary gas chromatography. Brochez, V., Van Heuverswyn, D., Diniz, J.A., De Potter, C.R., Van den Eeckhout, E.G. Lipids (1999)
- Differential effects of all-trans-retinoic acid, docosahexaenoic acid, and hexadecylphosphocholine on cisplatin-induced cytotoxicity and apoptosis in a cisplantin-sensitive and resistant human embryonal carcinoma cell line. Timmer-Bosscha, H., de Vries, E.G., Meijer, C., Oosterhuis, J.W., Mulder, N.H. Cancer Chemother. Pharmacol. (1998)
- Antitumor effects of alkylphosphocholines in different murine tumor models: use of liposomal preparations. Zeisig, R., Fichtner, I., Arndt, D., Jungmann, S. Anticancer Drugs (1991)
- Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. Pérez-Victoria, F.J., Gamarro, F., Ouellette, M., Castanys, S. J. Biol. Chem. (2003)
- The anti-leishmanial drug miltefosine causes insulin resistance in skeletal muscle cells in vitro. Verma, N.K., Dey, C.S. Diabetologia (2006)
- Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Walochnik, J., Duchêne, M., Seifert, K., Obwaller, A., Hottkowitz, T., Wiedermann, G., Eibl, H., Aspöck, H. Antimicrob. Agents Chemother. (2002)
- Possible mechanism of miltefosine-mediated death of Leishmania donovani. Verma, N.K., Dey, C.S. Antimicrob. Agents Chemother. (2004)
- Miltefosine Affects Lipid Metabolism in Leishmania donovani Promastigotes. Rakotomanga, M., Blanc, S., Gaudin, K., Chaminade, P., Loiseau, P.M. Antimicrob. Agents Chemother. (2007)
- Hexadecylphosphocholine inhibits translocation of CTP:choline-phosphate cytidylyltransferase in Madin-Darby canine kidney cells. Geilen, C.C., Wieder, T., Reutter, W. J. Biol. Chem. (1992)
- Growth inhibition of human mammary carcinoma by liposomal hexadecylphosphocholine: Participation of activated macrophages in the antitumor mechanism. Eue, I. Int. J. Cancer (2001)
- Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. Murray, H.W., Delph-Etienne, S. J. Infect. Dis. (2000)
- Vesicle-mediated phosphatidylcholine reapposition to the plasma membrane following hormone-induced phospholipase D activation. Coletti, D., Silvestroni, L., Naro, F., Molinaro, M., Adamo, S., Palleschi, S. Exp. Cell Res. (2000)
- Interaction between Miltefosine and Amphotericin B: Consequences for Their Activities towards Intestinal Epithelial Cells and Leishmania donovani Promastigotes In Vitro. M??nez, C., Buyse, M., Besnard, M., Farinotti, R., Loiseau, P.M., Barratt, G. Antimicrob. Agents Chemother. (2006)
- Antagonism of phorbol-ester-stimulated phosphatidylcholine biosynthesis by the phospholipid analogue hexadecylphosphocholine. Wieder, T., Geilen, C.C., Reutter, W. Biochem. J. (1993)
- Bcl-2 plays a key role instead of mdr1 in the resistance to hexadecylphosphocholine in human epidermoid tumor cell line KB. Fu, D., Shi, Z., Wang, Y. Cancer Lett. (1999)
- Mumps virus can suppress the effective augmentation of HPC-induced apoptosis by IFN-gamma through disruption of IFN signaling in U937 cells. Hariya, Y., Yokosawa, N., Yonekura, N., Kohama, G., Fuji, N. Microbiol. Immunol. (2000)
- Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity. Lucas, L., Hernández-Alcoceba, R., Penalva, V., Lacal, J.C. Oncogene (2001)
- Miltefosine (Hexadecylphosphocholine) Inhibits Cytochrome c Oxidase in Leishmania donovani Promastigotes. Luque-Ortega, J.R., Rivas, L. Antimicrob. Agents Chemother. (2007)
- Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Rybczynska, M., Spitaler, M., Knebel, N.G., Boeck, G., Grunicke, H., Hofmann, J. Biochem. Pharmacol. (2001)
- Trial of oral miltefosine for visceral leishmaniasis. Sundar, S., Rosenkaimer, F., Makharia, M.K., Goyal, A.K., Mandal, A.K., Voss, A., Hilgard, P., Murray, H.W. Lancet (1998)
- Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. Leonard, R., Hardy, J., van Tienhoven, G., Houston, S., Simmonds, P., David, M., Mansi, J. J. Clin. Oncol. (2001)
- Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine. Murray, H.W. Antimicrob. Agents Chemother. (2000)